Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy - PubMed (original) (raw)
Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy
M Boccadoro et al. Br J Haematol. 1984 Dec.
Abstract
The kinetics of bone marrow plasma cells were evaluated by means of in vitro 3(H)thymidine incorporation in 143 patients with monoclonal gammopathies. Fifty-three patients had symptomatic multiple myeloma (MM) at diagnosis, nine were in stable remission, six in unstable remission, and 16 in the relapse phase. Thirty-seven patients were classified has having monoclonal gammopathy of undetermined significance (MGUS) and 22 as smouldering myeloma (SM). A thymidine labelling index (LI%) of greater than 3 at initial diagnosis predicted a very short survival. High LI% values (median 2.8 +/- 1.1) were also seen at relapse. However, the major new finding was that the LI% could be used to discriminate precisely between the SM-MGUS group and the MM patients including stage I disease (P less than 0.0001). Only one patient developed MM during follow up, that being 8 months after the initial diagnosis of SM. During the unmaintained stable remission (plateau) phase a low proliferative activity was also observed (LI% = 0.6 +/- 0.2). Thus the LI% was extremely useful in identification of both poor risk groups with a LI% greater than 3 and stable patients requiring no immediate therapy with a LI% less than 1. The ability to discriminate between MGUS and SM and stage I MM should prove particularly useful clinically.
Similar articles
- Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M, Durie BG, Frutiger Y, Gavarotti P, Redoglia V, Massaia M, D'Alberto M, Marmont F, Gallamini A, Tribalto M, et al. Boccadoro M, et al. Acta Haematol. 1987;78(4):239-42. doi: 10.1159/000205885. Acta Haematol. 1987. PMID: 3122489 - A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V, Ordeltova M, Bacovsky J, Vytrasova M, Sumna E, Martinek A, Horak P. Scudla V, et al. Neoplasma. 2003;50(5):363-71. Neoplasma. 2003. PMID: 14628090 - Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
Lokhorst HM, Boom SE, Terpstra W, Roholl P, Gerdes J, Bast BJ. Lokhorst HM, et al. Br J Haematol. 1988 Aug;69(4):477-81. doi: 10.1111/j.1365-2141.1988.tb02402.x. Br J Haematol. 1988. PMID: 3044442 - Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA, San-Miguel JF, Mateos MV, Rajkumar SV. Kyle RA, et al. Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. doi: 10.1016/j.hoc.2014.06.005. Epub 2014 Jul 22. Hematol Oncol Clin North Am. 2014. PMID: 25212882 Review. - Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J, Moehler T, Hundemer M. Hillengass J, et al. Recent Results Cancer Res. 2011;183:113-31. doi: 10.1007/978-3-540-85772-3_6. Recent Results Cancer Res. 2011. PMID: 21509683 Review.
Cited by
- Amino Acid and Proliferation PET/CT for the Diagnosis of Multiple Myeloma.
Minamimoto R. Minamimoto R. Front Nucl Med. 2022 Jan 6;1:796357. doi: 10.3389/fnume.2021.796357. eCollection 2021. Front Nucl Med. 2022. PMID: 39355641 Free PMC article. Review. - RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D. Emde-Rajaratnam M, et al. Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023. Front Immunol. 2023. PMID: 38035078 Free PMC article. - Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, Jevremovic D, Pearce KE, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Mellors PW, et al. Blood Adv. 2020 May 26;4(10):2236-2244. doi: 10.1182/bloodadvances.2019001275. Blood Adv. 2020. PMID: 32442300 Free PMC article. Clinical Trial. - Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.
Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Oyama T, Asao T, Matsumoto M, Sawamura M. Isoda A, et al. Cancer Sci. 2014 Nov;105(11):1496-502. doi: 10.1111/cas.12529. Epub 2014 Oct 9. Cancer Sci. 2014. PMID: 25220100 Free PMC article. - Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma.
Dementyeva E, Kryukov F, Kubiczkova L, Nemec P, Sevcikova S, Ihnatova I, Jarkovsky J, Minarik J, Stefanikova Z, Kuglik P, Hajek R. Dementyeva E, et al. J Transl Med. 2013 Mar 23;11:77. doi: 10.1186/1479-5876-11-77. J Transl Med. 2013. PMID: 23522059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources